Skip to main content

Table 3 Pathologic response to NACT according to Residual Cancer Burden (RCB) scoring [10].

From: Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial

Group

RCB

0

n (%)

I

n (%)

II

n (%)

III

n (%)

Control n = 27

8 (29.6)

2 (7.4)

6 (22.2)

11 (40.7)

Intervention n = 25

8 (32.0)

2 (8.0)

5 (20.0)

10 (40.0)

Total n = 52

16 (30.8)

4 (7.7)

11 (21.2)

21 (40.4)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us